Shots:
Driven by innovation and a steadfast commitment to advancing cutting-edge therapies, the biopharma industry experienced robust growth in 2024, marked by significant revenue milestones
With a projected compound annual growth rate (CAGR) of 12.87%, the global biopharma market is expected to reach $1.41 trillion by 2032. In 2024, Pfizer led the industry with total…
Shots:
Prescription drugs have an instrumental role in effectively controlling chronic diseases like heart-related conditions, diabetes, arthritis, hypertension, and cancer, among others. Unlike over-the-counter drugs, prescription drugs are advised not to be taken without the authorization of a doctor
In 2022, the global market size of prescription drugs was worth $1035.5B and is envisioned to…
Shots:
Dr. Harmony gave the details about the positive 12-month findings from the P-IIIb SOLAR trial of the first and only complete long-acting injectable regimen Cabenuva vs. Biktarvy
She also talked about the comparison of the Cabenuva regimen with the other existing & developing products for HIV including the Biktarvy regimen
The interview gives an…
Shots:
The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatments
Advancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…
Active Ingredient: bictegravir, emtricitabine, and tenofovir alafenamide
Strength: 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF/ 30 mg of BIC, 120 mg of FTC, and 15 mg of TAF
Dosage Form: Tablet
Mechanism of Action: HIV reverse transcriptase inhibitors
First Approval: US (07 Feb 2018), EU (25 Jun 2018)
Revenue1
Gilead's HIV drug, Biktarvy has…
Active Ingredients: Adalimumab
Strength: 40 mg/0.8 ml
Dosage Form: Syringe, Vial
Mechanism of Action: TNF-alpha inhibitors
First Approval: US (Dec 31, 2002), EU (Aug 09, 2003)
Revenue
Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…
The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years.
No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…

